“Molecular Switches” on mGluR Allosteric Ligands That Modulate Modes of Pharmacology
- 22 February 2011
- journal article
- review article
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 50 (13) , 2403-2410
Abstract
G-Protein-coupled receptors (GPCRs) represent the largest class of drug targets, accounting for more than 40% of marketed drugs; however, discovery efforts for many GPCRs have failed to provide viable drug candidates. Historically, drug discovery efforts have focused on developing ligands that act at the orthosteric site of the endogenous agonist. Recently, efforts have focused on functional assay paradigms and the discovery of ligands that act at allosteric sites to modulate receptor function in either a positive, negative, or neutral manner. Allosteric modulators have numerous advantages over orthosteric ligands, including high subtype selectivity; the ability to mimic physiological conditions; the lack of densensitization, downregulation, and internalization; and reduced side effects. Despite these virtues, challenging issues have now arisen for allosteric modulators of metabotropic glutamate receptors (mGluRs): shallow SAR, ligand-directed trafficking, and the identification of subtle “molecular switches” that modulate the modes of pharmacology. Here, we will discuss the impact of modest structural changes to multiple mGluR allosteric ligands scaffolds that unexpectedly modulate pharmacology and raise concerns over metabolism and the pharmacology of metabolites.Keywords
This publication has 53 references indexed in Scilit:
- Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs and partial antagonistsBioorganic & Medicinal Chemistry Letters, 2011
- Discovery of a Novel Chemical Class of mGlu5 Allosteric Ligands with Distinct Modes of PharmacologyACS Chemical Neuroscience, 2010
- Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4ACS Chemical Neuroscience, 2010
- Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: Development of a potent and highly selective M1 PAMBioorganic & Medicinal Chemistry Letters, 2010
- Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTSBioorganic & Medicinal Chemistry Letters, 2009
- Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotypeBioorganic & Medicinal Chemistry Letters, 2009
- Synthesis, SAR and Unanticipated Pharmacological Profiles of Analogues of the mGluR5 Ago‐potentiator ADX‐47273ChemMedChem, 2009
- Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disordersTrends in Pharmacological Sciences, 2009
- Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophreniaTrends in Pharmacological Sciences, 2009
- Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffoldBioorganic & Medicinal Chemistry Letters, 2008